<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00208494</url>
  </required_header>
  <id_info>
    <org_study_id>03062</org_study_id>
    <nct_id>NCT00208494</nct_id>
  </id_info>
  <brief_title>Metal on Metal Versus Ceramic on Metal Hip Replacement</brief_title>
  <official_title>Comparative Study to Evaluate the Safety and Efficacy of the DePuy Ceramic-on-metal Total Hip Prosthesis Versus the DePuy Metal-on-metal Total Hip Prosthesis Through Clinical and Radiographical Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DePuy Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DePuy Orthopaedics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the performance of artificial hips with metal heads
      and metal sockets to artificial hips with ceramic heads articulating with metal socket
      components. The success of the total hip arthroplasty (THA) will be based upon all of the
      following clinical and radiographic criteria being met at the two-year evaluation: (1) the
      patient's clinical results as measured using modified Harris Hip evaluation rating system,
      and the absence of a complication that requires the surgical removal or replacement of a
      component; and (2) radiographic findings at study endpoint (i.e., two years follow-up).
      Clinical and radiographic success at two (2) years postoperative is required for the study
      hip to be deemed successful.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multi-center, randomized, single blind, controlled clinical
      investigation comparing the safety and efficacy of the cementless Ceramic on Metal total hip
      prostheses versus the cementless Metal on Metal total hip prostheses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Success/Failure</measure>
    <time_frame>At 24 months</time_frame>
    <description>The composite success/failure of the implant was made up of radiographic, clinical and revision data. Radiographic success was determined by femoral subsidence =/&lt; 2mm, acetabular migration =/&lt; 2mm, cup inclination =/&lt; 4Â°, no acetabular or femoral osteolysis, and acetabular and femoral lucencies less than 50% of visible porous coating. Clinical success was determined by a Harris Hip score equal to or greater than 80. A hip (patient) was considered to be a composite success at study endpoint if it was a radiographic and clinical success and no revision of any component had taken place.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Non-inflammatory Joint Diseases</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ceramic-on-metal total hip implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metal-on-metal total hip implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total Hip Replacement</intervention_name>
    <description>Total hip replacement</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Biolox Delta head; Ultamet insert; Pinnacle Acetabular shell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total hip replacement</intervention_name>
    <description>Total hip replacement</description>
    <arm_group_label>B</arm_group_label>
    <other_name>CoCr M-head, Ultamet insert, Pinnacle Acetabular shell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to (or capable of) provide consent to participate in the clinical investigation
             prior to the day of the surgery.

          -  Skeletally mature (tibial and femoral epiphyses are closed)

          -  Undergoing cementless primary hip replacement surgery for Noninflammatory Degenerative
             Joint Disease

          -  Affected hip has a Harris Hip Score of 70 or lower and a Pain rating of Moderate or
             greater

          -  Radiographic Parameters:

          -  X-Ray Evaluation confirms the presence of NIDJD

          -  Femoral and acetabular bone stock is sufficient, regarding strength and shape, and is
             suitable to receive the implants

          -  No structural bone grafts required to support to prosthetic component(s)or to shape
             the bone to receive implant(s)

          -  Willing to have knowledge of treatment arm (CoM or MoM) withheld for a period of 24
             months post-operatively unless disclosure is legally and/or medically necessary

          -  Previous THA in contralateral hip that is greater than one (1) year postoperative and
             has a Harris Hip pain rating less than MILD

        Exclusion Criteria:

          -  Bilateral hip disease with the anticipated need for bilateral hip implant during study
             participation (i.e., within the next 24 months)

          -  THA required for the revision of a previously failed THA

          -  Suffering from inflammatory arthritis

          -  Prior prosthetic hip replacement

          -  Previous Girdlestone procedure or surgical fusion in the operative hip joint

          -  Above knee amputation of either the contralateral or ipsilateral leg

          -  Known allergy to metal (e.g. jewelry)

          -  The presence of highly communicable disease or diseases that may limit follow-up
             (e.g., immuno-compromised conditions, hepatitis, active tuberculosis, etc.)

          -  Significant neurological or musculoskeletal disorders or disease that may adversely
             affect gait or weight bearing (e.g., muscular dystrophy, multiple sclerosis)

          -  Conditions that may interfere with the total hip arthroplasty survival or outcome
             (e.g., Paget's disease, Charcot's disease)

          -  Unwilling or unable to comply with a rehabilitation program for a cementless THA or
             difficulty or inability to return for follow-up visits prescribed by the study
             protocol

          -  Known to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser

          -  Previous treatment for renal disease

          -  Any systemic steroid therapy, excluding inhalers, within three months prior to surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Scott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopaedic Specialty Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick G Kirk, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Shekhar S Desai, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Charles A Engh, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anderson Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ajai Cadambi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adult Orthopaedic Reconstruction Texas Hip and Knee Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C L Barnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Foundation for Musculoskeletal Research &amp; Education</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foundation for Musculoskeletal Research and Education</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Bay</city>
        <state>Florida</state>
        <zip>32905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson Clinic</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>July 11, 2011</results_first_submitted>
  <results_first_submitted_qc>July 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2011</results_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Inflammatory Degenerative Joint Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eleven sites enrolled 392 subjects who were then randomized into two groups. The investigational group, Ceramic-on-Metal (COM) and the control group, Metal-on-Metal (MOM). Two subjects were intraoperatively excluded, resulting in 194 subjects COM subjects and 196 MOM subjects.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ceramic-on-Metal (COM) Total Hip Implant</title>
          <description>The COM modular total hip prosthesis has a ceramic femoral head articulating with a metal alloy acetabular bearing insert.</description>
        </group>
        <group group_id="P2">
          <title>Metal-on-Metal (MOM) Total Hip Implant</title>
          <description>The MOM modular total hip prosthesis has a metal femoral head articulating with a metal alloy acetabular bearing insert.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ceramic-on-Metal (COM) Total Hip Implant</title>
          <description>The COM modular total hip prosthesis has a ceramic femoral head articulating with a metal alloy acetabular bearing insert.</description>
        </group>
        <group group_id="B2">
          <title>Metal-on-Metal (MOM) Total Hip Implant</title>
          <description>The MOM modular total hip prosthesis has a metal femoral head articulating with a metal alloy acetabular bearing insert.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="194"/>
            <count group_id="B2" value="196"/>
            <count group_id="B3" value="390"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="10.1"/>
                    <measurement group_id="B2" value="59.1" spread="9.5"/>
                    <measurement group_id="B3" value="59" spread="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Success/Failure</title>
        <description>The composite success/failure of the implant was made up of radiographic, clinical and revision data. Radiographic success was determined by femoral subsidence =/&lt; 2mm, acetabular migration =/&lt; 2mm, cup inclination =/&lt; 4Â°, no acetabular or femoral osteolysis, and acetabular and femoral lucencies less than 50% of visible porous coating. Clinical success was determined by a Harris Hip score equal to or greater than 80. A hip (patient) was considered to be a composite success at study endpoint if it was a radiographic and clinical success and no revision of any component had taken place.</description>
        <time_frame>At 24 months</time_frame>
        <population>Out of the 390 subjects, 84 subjects were removed from the analysis for the following reasons: 2 deaths (1 in each arm); 3 protocol violations (2 COM, 1 MOM); 28 bilateral (12 COM, 16 MOM); 39 subjects had no 24-month Harris Hip score (22 COM, 17 MOM); and 12 subjects had no 24-month x-ray (4 COM, 8 MOM).</population>
        <group_list>
          <group group_id="O1">
            <title>Ceramic-on-Metal (COM) Total Hip Implant</title>
            <description>The COM modular total hip prosthesis has a ceramic femoral head articulating with a metal alloy acetabular bearing insert.</description>
          </group>
          <group group_id="O2">
            <title>Metal-on-Metal (MOM) Total Hip Implant</title>
            <description>The MOM modular total hip prosthesis has a metal femoral head articulating with a metal alloy acetabular bearing insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Success/Failure</title>
          <description>The composite success/failure of the implant was made up of radiographic, clinical and revision data. Radiographic success was determined by femoral subsidence =/&lt; 2mm, acetabular migration =/&lt; 2mm, cup inclination =/&lt; 4Â°, no acetabular or femoral osteolysis, and acetabular and femoral lucencies less than 50% of visible porous coating. Clinical success was determined by a Harris Hip score equal to or greater than 80. A hip (patient) was considered to be a composite success at study endpoint if it was a radiographic and clinical success and no revision of any component had taken place.</description>
          <population>Out of the 390 subjects, 84 subjects were removed from the analysis for the following reasons: 2 deaths (1 in each arm); 3 protocol violations (2 COM, 1 MOM); 28 bilateral (12 COM, 16 MOM); 39 subjects had no 24-month Harris Hip score (22 COM, 17 MOM); and 12 subjects had no 24-month x-ray (4 COM, 8 MOM).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ceramic-on-Metal (COM) Total Hip Implant</title>
          <description>The COM modular total hip prosthesis has a ceramic femoral head articulating with a metal alloy acetabular bearing insert.</description>
        </group>
        <group group_id="E2">
          <title>Metal-on-Metal (MOM) Total Hip Implant</title>
          <description>The MOM modular total hip prosthesis has a metal femoral head articulating with a metal alloy acetabular bearing insert.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hematoma requiring drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Deep Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dislocation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="194"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central Nervous System</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Peripheral nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory system</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatological</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Operative Adverse Event (fracture of femur</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Operative Adverse Event (other complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Operative Adverse Event (seating acetabular prosthesis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="194"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="194"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="194"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptom</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="194"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound problem</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="194"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Trochanteric Bursitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="194"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="106" subjects_affected="106" subjects_at_risk="194"/>
                <counts group_id="E2" events="91" subjects_affected="91" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central Nervous System</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="194"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="194"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory system</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="194"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatological</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="194"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Hoag, MS, Project Leader, Clinical Research</name_or_title>
      <organization>DePuy Orthopaedics, Inc.</organization>
      <phone>574-372-7399</phone>
      <email>JHoag2@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

